Inflammation May Be the Hidden Link Between Sleep, Smoking and Late-Life Depression

Depression in later life is one of the most stubborn and underappreciated public health problems of our time, and a new study suggests that the key to understanding it may be flowing quietly through the bloodstream. Researchers led by Li Yang of Shandong Second Medical University in China have found evidence that systemic inflammation, measured by levels of C-reactive protein (CRP), acts as a biological bridge connecting three well-known risk factors—sleep disorders, smoking, and multimorbidity—to depression in older adults. The findings, published in Current Psychology, add a striking twist: inflammation appears to mediate each of these pathways, but in very different ways and to very different degrees.

The research team drew on cross-sectional survey data collected from older adults through questionnaires and blood tests, using data from the United States National Health and Nutrition Examination Survey (NHANES), a nationally representative program whose protocols were approved by the NCHS Ethics Review Board. Their analytical strategy was layered. First, univariate analysis using chi-squared tests identified which groups of older adults carried higher rates of depression. Then Spearman correlation explored the associations between variables. Finally, and most importantly, the team used the Process plugin for Bootstrap mediation effect testing, a statistical technique that estimates whether a third variable—in this case CRP—carries part of the effect from a risk factor to the outcome.

The initial screen confirmed what much prior research had hinted at. Older adults with lower educational attainment, those who were widowed, divorced, separated, or never married, current smokers, people living with multiple chronic conditions, and those suffering from sleep disorders all showed significantly higher rates of depression. Each of these factors has been studied extensively on its own, but what makes the new work distinctive is that it asks a deeper mechanistic question: does inflammation explain how these disparate exposures converge on the same psychiatric outcome?

C-reactive protein is the body’s most widely used sentinel of systemic inflammation. Produced by the liver in response to interleukin-6 and other inflammatory signals, CRP rises when tissues are stressed, infected, or chronically damaged. Over the past two decades, a large body of research has linked elevated CRP to depression, with meta-analyses reporting that a substantial subset of people with depression show low-grade inflammation. What has remained murkier is whether CRP actually sits on the causal path between specific risk factors and depression, or whether it is merely a fellow traveler. The new study tackles that question directly, and the answers it produces are anything but uniform.

For sleep disturbances, the story follows the intuitive direction. Sleep disorders were associated with elevated CRP levels (β = 0.169, P < 0.01), and those higher CRP levels in turn were associated with an increased risk of depression. In statistical terms, CRP partially mediated the relationship, with the indirect effect accounting for 1.98 percent of the total effect. That percentage may look small, but the pattern matters: disrupted sleep appears to fan inflammatory signaling, and that inflammation contributes a measurable slice of the excess depression risk. The finding aligns with a growing literature connecting poor sleep to raised levels of CRP and other inflammatory markers, and with mediation analyses in large community samples such as NHANES that have reported similar pathways from sleep disturbance through inflammation to depressive symptoms.

Multimorbidity—the co-occurrence of two or more chronic conditions such as diabetes, cardiovascular disease, or arthritis—told a parallel story. Older adults burdened by multiple illnesses showed higher CRP levels (β = 0.135, P < 0.05), and again the inflammatory marker partially mediated the link to depression, with the indirect effect accounting for 5.07 percent of the total effect. This makes biological sense: accumulating chronic diseases generate ongoing tissue damage and immune activation, keeping the inflammatory system in a state of low-grade alert. Prior studies have already tied inflammation to the burden of multimorbidity and to its downstream consequences, including functional disability and dementia risk. The new results suggest that depression should be added to the list of outcomes that chronic disease load transmits partly through inflammation.

The smoking pathway, however, delivered the study’s most surprising result. In the statistical model, current smoking was associated with lower CRP levels (β = -0.087, P < 0.01), and lower CRP levels were in turn associated with a reduced risk of depression—so that inflammation constituted what the researchers describe as full mediation, with the indirect effect accounting for 24.75 percent of the total effect. In other words, the entire relationship between smoking and depression in this model ran through the CRP pathway, and it ran in a direction that contradicts the common assumption that smoking simply inflames the body. The authors themselves frame this cautiously as a feature of the statistical model, and the finding sits awkwardly alongside studies reporting that smoking history and cessation influence inflammatory markers in complex ways. It is a result that will demand replication and closer scrutiny, but it underscores how heterogeneous the biology behind late-life depression may be.

Why would inflammation influence mood at all? Neuroimaging research offers clues. Studies of functional and structural MRI have shown that inflammation can alter activity in brain circuits governing reward, threat processing, and emotional regulation, and can affect neurotransmitter metabolism, including the tryptophan-kynurenine pathway that diverts precursors of serotonin toward neurotoxic metabolites. In older adults, whose brains may be more vulnerable to inflammatory insults because of vascular changes and declining resilience, this mechanism could be particularly consequential. CRP itself does not cross the blood-brain barrier easily, but it serves as a reliable proxy for the inflammatory milieu that does reach the brain, making it a practical biomarker for population-level research.

The practical implications of the study are potentially significant. If systemic inflammation is a common biological link connecting sleep problems, chronic disease, and smoking to depression, then monitoring CRP in at-risk older adults could help clinicians identify who is most likely to slide into depressive illness. The authors suggest that tailored inflammation monitoring and intervention strategies for different at-risk populations may help prevent depression in older adults. That could mean aggressive management of chronic diseases to dampen inflammatory load, treatment of sleep disorders before they ignite immune activation, and smoking cessation programs—though the counterintuitive smoking-CRP finding suggests that the intervention logic for smokers may be more complicated than expected and requires further study.

As with all cross-sectional research, important caveats apply. The data capture a single moment in time, so the direction of causality between inflammation, risk factors, and depression cannot be definitively established; depression itself can worsen sleep, encourage smoking, and elevate inflammatory markers. The mediation percentages, particularly the small indirect effects for sleep and multimorbidity, indicate that inflammation explains only a fraction of the overall associations, leaving room for psychological, social, and behavioral mechanisms. Still, the study’s central message is compelling and testable: the road to late-life depression may run, at least in part, through the immune system. If future longitudinal and interventional studies confirm that lowering inflammation reduces depression risk in vulnerable older adults, a simple blood test could become an unexpected ally in one of the most pressing mental health challenges of an aging world.

Subject of Research: The mediating role of C-reactive protein in the association between sleep disorders, smoking, multimorbidity and depression in older adults

Article Title: The relationship between sleep disorders, smoking, and multimorbidity with depression in older adults: The mediating role of inflammation

Article References: Yang, L., Zhang, Y., Yuan, J.-B., Du, S.-X., Zhu, S.-H., Zheng, X.-M., & Cui, J.-W. (2026). The relationship between sleep disorders, smoking, and multimorbidity with depression in older adults: The mediating role of inflammation. Current Psychology, 45(19), Article 1584. https://doi.org/10.1007/s12144-026-10014-x

Image Credits: AI Generated

DOI: 10.1007/s12144-026-10014-x

Keywords: geriatric depression, C-reactive protein, inflammation, sleep disorders, smoking, multimorbidity, mediation analysis, NHANES, older adults, mental health, biomarkers, public health